What's in AbbVie (prior sponsor, Abbott)'s pipeline?

AbbVie (prior sponsor, Abbott) has 30 drugs in our index: 0 marketed, 0 filed, 10 in Phase 3, 14 in Phase 2, 6 in Phase 1.

Which companies overlap with AbbVie (prior sponsor, Abbott)'s portfolio?

Top competitors by shared drug class: AbbVie, GlaxoSmithKline, Sanofi, Merck Sharp & Dohme LLC, Centocor, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/abbvie-prior-sponsor-abbott.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

AbbVie (prior sponsor, Abbott) — Portfolio Competitive Intelligence Brief

AbbVie (prior sponsor, Abbott) pipeline: 0 marketed, 0 filed, 10 Phase 3, 14 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 10 Phase 3 14 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ABT-450/ritonavir	ABT-450/ritonavir	phase 3	Hepatitis C virus NS3/4A protease inhibitor	HCV NS3/4A serine protease	Virology / Hepatology
Placebo for ABT-333	Placebo for ABT-333	phase 3
ABT-450/r/ABT-267, ABT-333	ABT-450/r/ABT-267, ABT-333	phase 3	HCV protease inhibitor and non-nucleoside polymerase inhibitor combination	HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase	Virology / Hepatology
Placebo (PBO) oral capsules	Placebo (PBO) oral capsules	phase 3
Leuprolide Acetate 3 Month Depot	Leuprolide Acetate 3 Month Depot	phase 3	GnRH agonist	GnRH receptor	Oncology; Endocrinology
Placebo for ABT-450/r/ABT-267	Placebo for ABT-450/r/ABT-267	phase 3			Hepatology
ABT-267	ABT-267	phase 3	CCR2 antagonist	CCR2 (C-C chemokine receptor type 2)	Immunology / Inflammation
ABT-712	ABT-712	phase 3	FGFR1 inhibitor	FGFR1 (Fibroblast Growth Factor Receptor 1)	Oncology
ABT-333	ABT-333	phase 3	Non-nucleoside NS5B polymerase inhibitor	HCV NS5B RNA-dependent RNA polymerase	Virology / Hepatology
Open-label Adalimumab	Open-label Adalimumab	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)	Immunology

Therapeutic area mix

Oncology · 4
Immunology · 3
Virology / Hepatology · 3
Cardiovascular · 2
Immunology / Inflammation · 1
Immunology / Respiratory · 1
Infectious Diseases · 1
Multiple Sclerosis, Autoimmune Diseases · 1
Hepatology · 1
Oncology; Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Sanofi · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Centocor, Inc. · 2 shared drug classes
Bayer · 2 shared drug classes
Abbott · 2 shared drug classes
AstraZeneca · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for AbbVie (prior sponsor, Abbott):

Cite this brief

Drug Landscape (2026). AbbVie (prior sponsor, Abbott) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abbvie-prior-sponsor-abbott. Accessed 2026-05-16.